ClinicalTrials.gg
CompletedNCT06117605SEPTIC-EDUpdated Sep 19, 2024

Sepsis Electronic Prompting for Timely Intervention and Care for Emergency Department Patients

An interventional study of Nurse SIRS alert and Prescribing clinician SIRS alert in Sepsis, Electronic Health Records and Clinical Decision Support Systems, sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Columbia University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
25,668
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to study systemic inflammatory response syndrome (SIRS) electronic health record (EHR) alerts for sepsis in the emergency department (ED). The main question it aims to answer is: do nurse alerts, prescribing clinician alerts, or both nurse and prescribing clinician alerts improve time to sepsis treatment for patients in the ED?

Nurses and prescribing clinicians will receive SIRS alerts based on the group to which the patient is randomly assigned. Researchers will compare four groups: no alerts, nurse alerts only, prescribing clinician alerts only, or both nurse and prescribing clinician alerts.

Read the detailed description

SEPTIC is a master protocol for two trials on distinct subpopulations: emergency department (ED) patients and inpatients. This protocol "ID: AAAU1002 - ED" describes the ED subpopulation study while "ID: AAAU1002 - IP" describes the inpatient subpopulation study.

Sepsis is a major cause of death both globally and in the United States. Early identification and treatment of sepsis are crucial for improving outcomes. International guidelines recommend hospital sepsis screening programs, which are commonly implemented in the electronic health record (EHR) as an interruptive screening alert based on systemic inflammatory response syndrome (SIRS) criteria. Despite widespread use, it is unknown whether these sepsis screening and alert tools improve the delivery of high-quality sepsis care. This study tests interruptive (pop-up) EHR alerts. Epic Systems, the company that produces the EHR, refers to these types of alerts as BestPractice Advisories (BPAs).

02

Conditions studied

  • Sepsis
  • Electronic Health Records
  • Clinical Decision Support Systems

Browse trials for

Keywords

  • sepsis
  • alerts
  • clinical decision support systems
  • informatics
  • health information technology
03

In context

Sepsis

1,946 studies on the registry are indexed under Sepsis; 471 are open to participants now.

This study's enrollment of 25,668 is above the median of 105 across 918 interventional studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Columbia University is the lead sponsor of 1,135 studies on the registry; 195 are open to participants now.

Of its 179 completed or terminated interventional studies of FDA-regulated products, 146 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient Inclusion Criteria:

  • age > 18 years-old
  • meets SIRS criteria
  • physically located in the emergency department
  • not located in a hospital unit that takes care of pregnant and peri-partum patients
  • not SARS-COV-2 PCR positive in past 7 days
  • does not have an active order for "comfort measures only"

Patient Exclusion Criteria:

  • already having sepsis treatment ordered (if prescribing clinician alert) or collected/completed (if nurse alert)
  • already enrolled in the SEPTIC study (including as an emergency department patient or as an inpatient)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
25,668 participants (actual)

Study arms

  • No intervention
    No alert

    Participants will receive no physician alert or registered nurse (RN) alert.

  • Experimental
    Nurse alert

    Participants will receive RN alert.

    Other: Nurse SIRS alert

  • Experimental
    Prescribing clinician alert

    Participants will receive physician alert.

    Other: Prescribing clinician SIRS alert

  • Experimental
    Nurse alert and prescribing clinician alert

    Participants will receive physician alert and RN alert.

    Other: Nurse SIRS alert · Other: Prescribing clinician SIRS alert

Interventions

  • OtherNurse SIRS alert

    An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.

  • OtherPrescribing clinician SIRS alert

    An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.

06

What researchers measure

Primary outcomes

  1. Percentage of patients treated with Surviving Sepsis Campaign (SSC) hour-1 bundle

    The primary outcome is whether a patient receives a modified SSC hour-1 bundle within three hours from the time of first SIRS alert. The modified SSC hour-1 bundle includes (1) lactate lab collected, (2) two blood cultures collected, (3) new intravenous antimicrobial administration (from the Centers for Disease Control and Prevention (CDC) Adult Sepsis Event (ASE) list). Patients will be tallied.

    Time frame: Up to 3 hours

Secondary outcomes

  1. Time to blood culture order

    Time from the first SIRS alert until two blood cultures ordered in all patients and the subgroups of patients with CDC ASE, CDC BSE, and Sepsis-3 sepsis definitions. This will be measured in minutes.

    Time frame: 24 hours

  2. Time to blood culture collection

    Time from the first SIRS alert until two blood cultures collected in all patients and the subgroups of patients with CDC ASE, CDC BSE, and Sepsis-3 sepsis definitions. This will be measured in minutes.

    Time frame: 24 hours

  3. Time to lactate order

    Time from the first SIRS alert until lactate lab ordered in all patients and the subgroups of patients with CDC ASE, CDC BSE, and Sepsis-3 sepsis definitions. This will be measured in minutes.

    Time frame: 24 hours

  4. Time to lactate collection

    Time from the first SIRS alert until lactate lab collected in all patients and the subgroups of patients with CDC ASE, CDC BSE, and Sepsis-3 sepsis definitions. This will be measured in minutes.

    Time frame: 24 hours

  5. Time to antibiotic order

    Time from the first SIRS alert until new antibiotic order in all patients and the subgroups of patients with CDC ASE, CDC BSE, and Sepsis-3 sepsis definitions. This will be measured in minutes.

    Time frame: 24 hours

  6. Time to antibiotic treatment

    Time from the first SIRS alert until new antibiotic administration in all patients and the subgroups of patients with CDC ASE, CDC BSE, and Sepsis-3 sepsis definitions. This will be measured in minutes.

    Time frame: 24 hours

  7. Sepsis incidence

    Sepsis incidence (CDC ASE, CDC BSE, Sepsis-3) across all alerting groups. Events will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  8. Percentage of patients transferred to ICU transfer

    Intensive care unit (ICU) transfers for patients not in the ICU at the time of first SIRS alert will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  9. Median number of days of hospitalization

    This is to determine the average length of stay in the hospital. Days will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  10. Percentage of patients discharged as deceased or discharged to hospice

    This is to measure the outcomes ended in death or hospice. Outcomes will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  11. Percentage of patients discharged home

    This is to measure the outcomes ended in returning to home. Outcomes will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  12. Percentage of patients discharged to rehab

    This is to measure the outcomes ended in rehab. Outcomes will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  13. Percentage of patients discharged to skilled nursing facility

    This is to measure the outcomes ended in skilled nursing facility. Outcomes will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  14. Percentage inpatient mortality at 90 days

    This is to measure inpatient mortality. Deaths will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  15. Number of positive blood cultures

    Positive blood cultures will be determined by blood tests. Positive cultures will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  16. Adverse antibiotic events

    This is defined as new antibiotic allergy documented in 14 days after first SIRS alert or C. difficile infection or multi-drug resistant organism infection within 7-90 days of first SIRS alert. Events will be recorded and tallied up to 90 days from first SIRS alert or discharge, whichever occurs first.

    Time frame: Up to 90 days

  17. Time to modified SSC hour-1 bundle completion

    Time interval from first SIRS alert to a modified SSC hour-1 bundle completion, censored at 24 hours after the first alert time, in all patients and the subgroups of patients with CDC ASE, CDC Bacteraemia/Fungemia Shock Event (BSE), and Sepsis-3 sepsis definitions. This will be measured in minutes.

    Time frame: 24 hours

07

Study locations

1 site
  • NewYork-Presbyterian Hospitals
    New York, New York 10032, United States
08

References and documents

Publications

  • Ranard BL, Qian M, Cummings MJ, Zhang DY, Lee SM, Beitler JR, Applebaum JR, Schenck EJ, Mohamed H, Trepp R, Hsu H, Scofi J, Southern WN, Rossetti SC, Yip NH, Brodie D, Sharma M, Fertel BS, Adelman JS. Pragmatic, multicentre, factorial, randomised controlled trial of sepsis electronic prompting for timely intervention and care (SEPTIC trial): a protocol. BMJ Open. 2025 Aug 11;15(8):e088792. doi: 10.1136/bmjopen-2024-088792. PubMed 40789731 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Apr 2024, 5 months.

Of 246 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 5 months is below that.

Counting every sponsor, half of 267 studies reached it within 22 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 7, 2023
StartActual
Nov 14, 2023
Primary completionActual
Apr 22, 2024
CompletionActual
Jul 22, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06117605
Responsible party
Jason Adelman (Associate Professor of Medicine, Columbia University) — Principal investigator
First posted
Nov 7, 2023
Start date
Nov 14, 2023
Primary completion
Apr 22, 2024
Completion
Jul 22, 2024
Last update
Sep 19, 2024

Study contacts

Benjamin L Ranard, MD, MSHP
study director · Columbia University
Jason S Adelman, MD, MS
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion